These results highlight the therapeutic potential of targeting the c-Abl/TFEB pathway to restore lysosomal function in lysosomal storage disorders and suggest broader implications for neurodegenerative diseases associated with oxidative stress and lysosomal dysfunction. The gene discussed is ABL1; the disease is neurodegenerative disease.